Zdrowie i gospodarka · 05/08/2021
FDA Clears Way for Approval of Pazopanib Hydrochloride Tablets, 400mg
The US Food and Drug Administration (FDA) has ruled that VOTRIENT (pazopanib hydrochloride) tablets, 400mg, were not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications (ANDAs) for the medication.